Equity Overview
Price & Market Data
Price: $0.473
Daily Change: -$0.0103 / 2.18%
Daily Range: $0.45 - $0.48
Market Cap: $19,291,178
Daily Volume: 119,967
Performance Metrics
1 Week: -0.40%
1 Month: -56.61%
3 Months: -79.70%
6 Months: -81.23%
1 Year: -66.57%
YTD: -53.17%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.